{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:07:57Z","timestamp":1790694477052,"version":"4.1.0"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T00:00:00Z","timestamp":1692921600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005778","name":"Central University of Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005778","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011272","name":"FP7 Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.ejpb.2023.08.014","type":"journal-article","created":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T05:15:09Z","timestamp":1692940509000},"page":"124-138","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Particulate antigens administrated by intranasal and intravaginal routes in a prime-boost strategy improve HIV-specific TFH generation, high-quality antibodies and long-lasting mucosal immunity"],"prefix":"10.1016","volume":"191","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4140-498X","authenticated-orcid":false,"given":"Thomas","family":"Vazquez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e9a","family":"Torrieri-Damard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabien","family":"Pitoiset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9atrice","family":"Levacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Vigneron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luzia","family":"Mayr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faustine","family":"Brimaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Bonnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Moog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Klatzmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8921-5478","authenticated-orcid":false,"given":"Bertrand","family":"Bellier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2023.08.014_b0005","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1126\/science.6189183","article-title":"Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS)","volume":"220","author":"Barr\u00e9-Sinoussi","year":"1983","journal-title":"Science"},{"key":"10.1016\/j.ejpb.2023.08.014_b0010","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa0908492","article-title":"Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand","volume":"361","author":"Rerks-Ngarm","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejpb.2023.08.014_b0015","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2031499","article-title":"Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120-MF59 in Adults","volume":"384","author":"Gray","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejpb.2023.08.014_b0020","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1586\/14760584.6.3.401","article-title":"Implication of nanoparticles\/microparticles in mucosal vaccine delivery","volume":"6","author":"Vyas","year":"2007","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.ejpb.2023.08.014_b0025","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.00345","article-title":"Virus-Like Particle, Liposome, and Polymeric Particle-Based Vaccines against HIV-1","volume":"9","author":"Gao","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejpb.2023.08.014_b0030","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.immuni.2011.01.015","article-title":"Immunization with HIV-1 gp41 Subunit Virosomes Induces Mucosal Antibodies Protecting Nonhuman Primates against Vaginal SHIV Challenges","volume":"34","author":"Bomsel","year":"2011","journal-title":"Immunity"},{"key":"10.1016\/j.ejpb.2023.08.014_b0035","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.573157","article-title":"Design Concepts of Virus-Like Particle-Based HIV-1 Vaccines","volume":"11","author":"Chen","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejpb.2023.08.014_b0040","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1038\/s41591-021-01574-5","article-title":"A multiclade env-gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques","volume":"27","author":"Zhang","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejpb.2023.08.014_b0045","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41541-023-00648-4","article-title":"An engineered HIV-1 Gag-based VLP displaying high antigen density induces strong antibody-dependent functional immune responses","volume":"8","author":"Tarr\u00e9s-Freixas","year":"2023","journal-title":"npj Vaccines"},{"key":"10.1016\/j.ejpb.2023.08.014_b0050","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1586\/14760584.2015.1046440","article-title":"Enveloped virus-like particle platforms: vaccines of the future?","volume":"14","author":"Pitoiset","year":"2015","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.ejpb.2023.08.014_b0055","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S1074-7613(04)00053-6","article-title":"Immunobiology of mucosal HIV infection and the basis for development of a new generation of mucosal AIDS vaccines","volume":"20","author":"Belyakov","year":"2004","journal-title":"Immunity"},{"key":"10.1016\/j.ejpb.2023.08.014_b0060","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/nri1777","article-title":"Mucosal vaccines: the promise and the challenge","volume":"6","author":"Neutra","year":"2006","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ejpb.2023.08.014_b0065","doi-asserted-by":"crossref","first-page":"6883","DOI":"10.4049\/jimmunol.0901466","article-title":"What Role Does the Route of Immunization Play in the Generation of Protective Immunity against Mucosal Pathogens?","volume":"183","author":"Belyakov","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejpb.2023.08.014_b0070","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/mi.2009.89","article-title":"HIV-1 gp41-specific monoclonal mucosal IgAs derived from highly exposed but IgG-seronegative individuals block HIV-1 epithelial transcytosis and neutralize CD4(+) cell infection: an IgA gene and functional analysis","volume":"2","author":"Tudor","year":"2009","journal-title":"Mucosal Immunol."},{"key":"10.1016\/j.ejpb.2023.08.014_b0075","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1097\/QAD.0b013e3282f56b64","article-title":"HIV-neutralizing immunoglobulin A and HIV-specific proliferation are independently associated with reduced HIV acquisition in Kenyan sex workers","volume":"22","author":"Hirbod","year":"2008","journal-title":"AIDS"},{"key":"10.1016\/j.ejpb.2023.08.014_b0080","doi-asserted-by":"crossref","first-page":"5170","DOI":"10.4049\/jimmunol.165.9.5170","article-title":"Mucosal and Plasma IgA from HIV-1-Exposed Uninfected Individuals Inhibit HIV-1 Transcytosis Across Human Epithelial Cells","volume":"165","author":"Devito","year":"2000","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejpb.2023.08.014_b0085","first-page":"157","article-title":"Mucosal immunity and HIV-1 infection: applications for mucosal AIDS vaccine development","volume":"354","author":"Belyakov","year":"2012","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.ejpb.2023.08.014_b0090","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.3389\/fmicb.2017.02091","article-title":"Emerging Targets for Developing T Cell-Mediated Vaccines for Human Immunodeficiency Virus (HIV)-1","volume":"8","author":"Wijesundara","year":"2017","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.ejpb.2023.08.014_b0095","doi-asserted-by":"crossref","first-page":"4512","DOI":"10.1016\/j.vaccine.2011.04.023","article-title":"Intravaginal immunization using the recombinant HIV-1 clade-C trimeric envelope glycoprotein CN54gp140 formulated within lyophilized solid dosage forms","volume":"29","author":"Donnelly","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.ejpb.2023.08.014_b0100","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jconrel.2017.01.018","article-title":"Intravaginal immunisation using a novel antigen-releasing ring device elicits robust vaccine antigen-specific systemic and mucosal humoral immune responses","volume":"249","author":"McKay","year":"2017","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2023.08.014_b0105","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1089\/0889222041725253","article-title":"An SHIV DNA\/MVA rectal vaccination in macaques provides systemic and mucosal virus-specific responses and protection against AIDS","volume":"20","author":"Wang","year":"2004","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"10.1016\/j.ejpb.2023.08.014_b0110","doi-asserted-by":"crossref","first-page":"7481","DOI":"10.1128\/IAI.69.12.7481-7486.2001","article-title":"Nasal and Vaginal Vaccinations Have Differential Effects on Antibody Responses in Vaginal and Cervical Secretions in Humans","volume":"69","author":"Johansson","year":"2001","journal-title":"Infect. Immun."},{"key":"10.1016\/j.ejpb.2023.08.014_b0115","doi-asserted-by":"crossref","first-page":"13699","DOI":"10.1128\/JVI.02279-14","article-title":"Vaginal memory T cells induced by intranasal vaccination are critical for protective T cell recruitment and prevention of genital HSV-2 disease","volume":"88","author":"Sato","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/j.ejpb.2023.08.014_b0120","doi-asserted-by":"crossref","first-page":"569","DOI":"10.3389\/fimmu.2017.00569","article-title":"Simultaneous Subcutaneous and Intranasal Administration of a CAF01-Adjuvanted Chlamydia Vaccine Elicits Elevated IgA and Protective Th1\/Th17 Responses in the Genital Tract","volume":"8","author":"Wern","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejpb.2023.08.014_b0125","doi-asserted-by":"crossref","first-page":"eabn1413","DOI":"10.1126\/scitranslmed.abn1413","article-title":"Intranasal vaccination with lipid-conjugated immunogens promotes antigen transmucosal uptake to drive mucosal and systemic immunity","volume":"14","author":"Hartwell","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ejpb.2023.08.014_b0130","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/j.vaccine.2012.05.025","article-title":"Recombinant retrovirus-derived virus-like particle-based vaccines induce hepatitis C virus-specific cellular and neutralizing immune responses in mice","volume":"31","author":"Huret","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.ejpb.2023.08.014_b0135","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1016\/j.vaccine.2005.11.034","article-title":"DNA vaccines encoding retrovirus-based virus-like particles induce efficient immune responses without adjuvant","volume":"24","author":"Bellier","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.ejpb.2023.08.014_b0140","doi-asserted-by":"crossref","first-page":"5772","DOI":"10.1016\/j.vaccine.2009.07.059","article-title":"DNA vaccines expressing retrovirus-like particles are efficient immunogens to induce neutralizing antibodies","volume":"27","author":"Bellier","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.ejpb.2023.08.014_b0145","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1056\/NEJMoa1113425","article-title":"Immune-correlates analysis of an HIV-1 vaccine efficacy trial","volume":"366","author":"Haynes","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejpb.2023.08.014_b0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-019-41506-5","article-title":"Mucosal and systemic SIV-specific cytotoxic CD4 + T cell hierarchy in protection following intranasal\/intramuscular recombinant pox-viral vaccination of pigtail macaques","volume":"9","author":"Khanna","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejpb.2023.08.014_b0155","doi-asserted-by":"crossref","first-page":"36658","DOI":"10.1038\/srep36658","article-title":"Mucosal vaccination with a live recombinant rhinovirus followed by intradermal DNA administration elicits potent and protective HIV-specific immune responses","volume":"6","author":"Tomusange","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejpb.2023.08.014_b0160","doi-asserted-by":"crossref","first-page":"7285","DOI":"10.1128\/JVI.00481-16","article-title":"Vaccine-Elicited Mucosal and Systemic Antibody Responses Are Associated with Reduced Simian Immunodeficiency Viremia in Infant Rhesus Macaques","volume":"90","author":"Jensen","year":"2016","journal-title":"J. Virol."},{"key":"10.1016\/j.ejpb.2023.08.014_b0175","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1128\/IAI.66.7.3390-3396.1998","article-title":"Differential Kinetics and Distribution of Antibodies in Serum and Nasal and Vaginal Secretions after Nasal and Oral Vaccination of Humans","volume":"66","author":"Rudin","year":"1998","journal-title":"Infect. Immun."},{"key":"10.1016\/j.ejpb.2023.08.014_b0180","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.623996","article-title":"Parainfluenza Virus 5 Priming Followed by SIV\/HIV Virus-Like-Particle Boosting Induces Potent and Durable Immune Responses in Nonhuman Primates","volume":"12","author":"Xiao","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejpb.2023.08.014_b0185","doi-asserted-by":"crossref","first-page":"e80559","DOI":"10.1371\/journal.pone.0080559","article-title":"A \u2018prime-pull\u2019 vaccine strategy has a modest effect on local and systemic antibody responses to HIV gp140 in mice","volume":"8","author":"Tregoning","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ejpb.2023.08.014_b0190","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41541-020-00277-1","article-title":"Recombinant MVA-prime elicits neutralizing antibody responses by inducing antigen-specific B cells in the germinal center","volume":"6","author":"Eslamizar","year":"2021","journal-title":"npj Vaccines"},{"key":"10.1016\/j.ejpb.2023.08.014_b0195","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1586\/14760584.7.1.43","article-title":"Exploiting viral properties for the rational design of modern vaccines","volume":"7","author":"Spohn","year":"2008","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.ejpb.2023.08.014_b0200","first-page":"53","article-title":"Virus-like particles for antigen delivery at mucosal surfaces","volume":"354","author":"Schneider-Ohrum","year":"2012","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.ejpb.2023.08.014_b0205","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01230-17","article-title":"Retrovirus-Based Virus-Like Particle Immunogenicity and Its Modulation by Toll-Like Receptor Activation","volume":"91","author":"Pitoiset","year":"2017","journal-title":"J. Virol."},{"key":"10.1016\/j.ejpb.2023.08.014_b0210","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1128\/JVI.01650-08","article-title":"Alphavirus-adjuvanted norovirus-like particle vaccines: heterologous, humoral, and mucosal immune responses protect against murine norovirus challenge","volume":"83","author":"LoBue","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/j.ejpb.2023.08.014_b0215","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1006\/viro.1998.9442","article-title":"Mucosal immunisation with papillomavirus virus-like particles elicits systemic and mucosal immunity in mice","volume":"252","author":"Liu","year":"1998","journal-title":"Virology"},{"key":"10.1016\/j.ejpb.2023.08.014_b0220","doi-asserted-by":"crossref","first-page":"5968","DOI":"10.1016\/j.vaccine.2007.05.052","article-title":"DNA-VLP prime-boost intra-nasal immunization induces cellular and humoral anti-HIV-1 systemic and mucosal immunity with cross-clade neutralizing activity","volume":"25","author":"Buonaguro","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.ejpb.2023.08.014_b0225","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1186\/s12985-017-0831-4","article-title":"Membrane-anchored CCL20 augments HIV Env-specific mucosal immune responses","volume":"14","author":"Sun","year":"2017","journal-title":"Virol. J."},{"key":"10.1016\/j.ejpb.2023.08.014_b0230","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00328-10","article-title":"Enhanced mucosal immune responses to HIV virus-like particles containing a membrane-anchored adjuvant","volume":"2","author":"Vassilieva","year":"2011","journal-title":"MBio"},{"key":"10.1016\/j.ejpb.2023.08.014_b0235","doi-asserted-by":"crossref","first-page":"e67412","DOI":"10.1371\/journal.pone.0067412","article-title":"Mucosal application of gp140 encoding DNA polyplexes to different tissues results in altered immunological outcomes in mice","volume":"8","author":"Mann","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ejpb.2023.08.014_b0245","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1128\/JVI.02544-12","article-title":"Antibodies with High Avidity to the gp120 Envelope Protein in Protection from Simian Immunodeficiency Virus SIVmac251 Acquisition in an Immunization Regimen That Mimics the RV-144 Thai Trial","volume":"87","author":"Pegu","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.ejpb.2023.08.014_b0250","doi-asserted-by":"crossref","first-page":"243ra88","DOI":"10.1126\/scitranslmed.3008992","article-title":"Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor","volume":"6","author":"Pegu","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ejpb.2023.08.014_b0255","doi-asserted-by":"crossref","first-page":"9019","DOI":"10.1073\/pnas.1301456110","article-title":"Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG","volume":"110","author":"Tomaras","year":"2013","journal-title":"Proc. Natl. Aacd. Sci. USA"},{"key":"10.1016\/j.ejpb.2023.08.014_b0260","doi-asserted-by":"crossref","first-page":"e53629","DOI":"10.1371\/journal.pone.0053629","article-title":"Analysis of V2 Antibody Responses Induced in Vaccinees in the ALVAC\/AIDSVAX HIV-1 Vaccine Efficacy Trial","volume":"8","author":"Zolla-Pazner","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ejpb.2023.08.014_b0265","doi-asserted-by":"crossref","first-page":"5166","DOI":"10.4049\/jimmunol.1102756","article-title":"The Thai Phase III Trial (RV144) Vaccine Regimen Induces T Cell Responses That Preferentially Target Epitopes within the V2 Region of HIV-1 Envelope","volume":"188","author":"de Souza","year":"2012","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejpb.2023.08.014_b0270","doi-asserted-by":"crossref","first-page":"e0193773","DOI":"10.1371\/journal.pone.0193773","article-title":"Characterization of broadly neutralizing antibody responses to HIV-1 in a cohort of long term non-progressors","volume":"13","author":"Gonz\u00e1lez","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.ejpb.2023.08.014_b0275","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002330","article-title":"A Prime-Boost Strategy Using Virus-Like Particles Pseudotyped for HCV Proteins Triggers Broadly Neutralizing Antibodies in Macaques","volume":"3","author":"Garrone","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ejpb.2023.08.014_b0280","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/mt.2010.222","article-title":"Intranasal DNA vaccination induces potent mucosal and systemic immune responses and cross-protective immunity against influenza viruses","volume":"19","author":"Torrieri-Dramard","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ejpb.2023.08.014_b0285","doi-asserted-by":"crossref","first-page":"13239","DOI":"10.1128\/JVI.01247-13","article-title":"Robust Neutralizing Antibodies Elicited by HIV-1 JRFL Envelope Glycoprotein Trimers in Nonhuman Primates","volume":"87","author":"Chakrabarti","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.ejpb.2023.08.014_b0290","doi-asserted-by":"crossref","first-page":"10103","DOI":"10.1128\/JVI.79.16.10103-10107.2005","article-title":"Recommendations for the Design and Use of Standard Virus Panels To Assess Neutralizing Antibody Responses Elicited by Candidate Human Immunodeficiency Virus Type 1 Vaccines","volume":"79","author":"Mascola","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.ejpb.2023.08.014_b0295","doi-asserted-by":"crossref","first-page":"10108","DOI":"10.1128\/JVI.79.16.10108-10125.2005","article-title":"Human Immunodeficiency Virus Type 1 env Clones from Acute and Early Subtype B Infections for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies","volume":"79","author":"Li","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.ejpb.2023.08.014_b0300","doi-asserted-by":"crossref","first-page":"12655","DOI":"10.1038\/s41598-017-12883-6","article-title":"Non-neutralizing Antibodies Targeting the V1V2 Domain of HIV Exhibit Strong Antibody-Dependent Cell-mediated Cytotoxic Activity","volume":"7","author":"Mayr","year":"2017","journal-title":"Sci. Rep."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641123002278?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641123002278?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:52:58Z","timestamp":1760547178000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641123002278"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":57,"alternative-id":["S0939641123002278"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2023.08.014","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Particulate antigens administrated by intranasal and intravaginal routes in a prime-boost strategy improve HIV-specific TFH generation, high-quality antibodies and long-lasting mucosal immunity","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2023.08.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}